Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
direct-acting antivirals
glecaprevir and pibrentasvir
hepatitis C virus
ledipasvir and sofosbuvir
relapse
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
medline:
5
9
2023
pubmed:
1
12
2022
entrez:
30
11
2022
Statut:
ppublish
Résumé
A patient with genotype 1b chronic hepatitis C virus who had been treated with pegylated interferon and ribavirin (RBV) was treated with glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks. A sustained virological response at post-treatment week 12 (SVR12) was achieved, but relapse occurred approximately 31 weeks after the end of treatment. The patient had a history of allergy to RBV and was treated with ledipasvir/sofosbuvir (LDV/SOF), achieving SVR12 and remaining hepatitis C virus-negative until 24 weeks after the completion of treatment. LDV/SOF can thus be a secondary treatment for GLE/PIB.
Identifiants
pubmed: 36450472
doi: 10.2169/internalmedicine.0865-22
pmc: PMC10518557
doi:
Substances chimiques
ledipasvir, sofosbuvir drug combination
0
Sofosbuvir
WJ6CA3ZU8B
ledipasvir
013TE6E4WV
glecaprevir
K6BUU8J72P
Antiviral Agents
0
pibrentasvir
2WU922TK3L
Ribavirin
49717AWG6K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2507-2511Références
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29084747
Hepatol Res. 2019 Jun;49(6):617-626
pubmed: 30849206
J Gastroenterol. 2018 Oct;53(10):1142-1150
pubmed: 29626296
PLoS One. 2016 Oct 24;11(10):e0165339
pubmed: 27776192
Hepatology. 1990 Oct;12(4 Pt 1):671-5
pubmed: 2170265
J Gastroenterol. 2019 Oct;54(10):916-927
pubmed: 30903385
J Gastroenterol. 2019 Mar;54(3):291-296
pubmed: 30334096
Viruses. 2021 Jun 16;13(6):
pubmed: 34208646
Int J Mol Sci. 2017 Apr 25;18(5):
pubmed: 28441362
Hepatol Int. 2018 Jul;12(4):356-367
pubmed: 30030720
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29180522
J Gastroenterol. 2018 Apr;53(4):557-565
pubmed: 28948366
J Gastroenterol. 2019 May;54(5):459-470
pubmed: 30612205
J Viral Hepat. 2018 Dec;25(12):1446-1451
pubmed: 29993164
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28193664
J Med Virol. 2019 Jan;91(1):102-106
pubmed: 30091810
Hepatology. 2018 Jul;68(1):380-383
pubmed: 29425404
J Gastroenterol. 2018 Apr;53(4):566-575
pubmed: 29052790
PLoS One. 2015 Apr 09;10(4):e0122844
pubmed: 25856426
Hepatol Res. 2017 Nov;47(12):1308-1316
pubmed: 28332272